AXSM vs. JAZZ, TEVA, SMMT, ITCI, GMAB, RDY, QGEN, MRNA, ASND, and VTRS
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "medical" sector.
Axsome Therapeutics vs. Its Competitors
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.
Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.
Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
Jazz Pharmaceuticals currently has a consensus price target of $184.00, indicating a potential upside of 67.39%. Axsome Therapeutics has a consensus price target of $172.33, indicating a potential upside of 65.85%. Given Jazz Pharmaceuticals' higher possible upside, equities research analysts clearly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.
In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 14 mentions for Jazz Pharmaceuticals and 8 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 1.05 beat Axsome Therapeutics' score of 0.80 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Jazz Pharmaceuticals beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AXSM) was last updated on 7/3/2025 by MarketBeat.com Staff
